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Abstract: Nucleoside analogues have proven to be highly successful chemotherapeutic agents in
the treatment of a wide variety of cancers. Several such compounds, including gemcitabine and
cytarabine, are the go-to option in first-line treatments. However, these materials do have limitations
and the development of next generation compounds remains a topic of significant interest and
necessity. Herein, we discuss recent advances in the chemical synthesis and biological evaluation
of nucleoside analogues as potential anticancer agents. Focus is paid to 4′-heteroatom substitution
of the furanose oxygen, 2′-, 3′-, 4′- and 5′-position ring modifications and the development of new
prodrug strategies for these materials.
Keywords: nucleoside analogue; anti-cancer; chemical synthesis; heteroatom replacement;
chemotherapeutic; prodrug
1. Introduction
A significant proportion of current chemotherapeutic treatments for cancer involve the use of
anti-metabolites, particularly modified nucleoside analogues that possess a capability to mimic native
purine or pyrimidine nucleosides which can disrupt metabolic and regulatory pathways [1]. These
molecules can be taken up by nucleoside transporters and then phosphorylated to their mono-, di- and
triphosphate forms where they are able to interfere with DNA/RNA synthesis and repair; for example,
by acting as chain terminators [2] or ribonucleotide reductase inhibitors [3]. Other notable modes of
action include epigenetic regulation, through inhibition of DNA regulatory proteins, such as DNA
methyltransferase [4]. Selected current examples of anticancer nucleoside analogues approved for
chemotherapeutic treatment regimens include capecitabine, gemcitabine 1, clofarabine 2 and cytarabine
(Ara-C) 3 (Figure 1).
  
Molecules 2020, 25, x; doi: www.mdpi.com/journal/molecules 
Review 
Recent Advances in the Chemical Synthesis and 
Evaluation of nticancer ucleoside nalogues 
Mieke Guinan 1, Caecilie Benckendorff 1, Mark Smith 2 and Gavin J. Miller 1,* 
1 Lennard-Jones Laboratory, School of Chemical and Physical Sciences, Keele University, Keele, 
Staffordshire, ST5 5BG, UK; m.guinan@keele.ac.uk (M.G.); c.m.m.benckendorff@keele.ac.uk (C.B.) 
2 Medicinal Chemistry Knowledge Center, Stanford ChEM-H, 290 Jane Stanford Way, Stanford, CA 94305, 
USA; mxsmith@stanford.edu 
* Correspondence: g.j.miller@keele.ac.uk 
Academic Editor: Derek J. McPhee 
Received: 2 April 2020; Accepted: 25 April 2020; Published: date 
 ucleoside analogues have proven to be highly successful chemotherapeutic agents in the 
rea ment of a wide variety of cancers. Several such compounds, including citabine  
 are the g -to pt on in first-line treatments. How v r, these materials do have 
limitations and th  development of next generation co pounds remain  a topic of significant 
intere t and necessity. Herein, we discuss recent advances n the chemical synthesis and biological 
eval ati n of nuc eoside analogues as potential anticancer agents. Focus is paid  4′-heteroa om 
substitutio  of the furanose oxygen, 2′-, 3′-, 4′- and 5′-posi  ri g mo ifications and the 
developmen  of new prodrug s rategies for these materials. 
  l ;  che ical s t i ; heteroato  replace e t; 
tic; prodrug 
 
1. I tro ctio   
 sig ifica t ro ortio  of c rre t c e ot era e tic treat e ts for ca cer i ol e t e se of 
a ti- etabolites, particularly modified nucleoside analogues that possess a capability to mimic 
native purine or pyrimidine nucleosides which can disrupt metabolic and regulatory pathways [1]. 
These molecules can be taken up by nucleoside transporters and then phosphorylated to their mono-, 
di- and triphosphate forms where they are able to interfere with DNA/RNA sy thesis and repair; for 
example, by acti g as chain terminators [2] or ribonucleotide reductase inhibitors [3]. Other notable 
modes of action include epi enetic regulation, through inhibition of DNA regulatory proteins, such 
as DNA methyltransferase [4]. Selected current examples of anticancer nucleoside analogues 
approved for chemotherapeutic treatment regimens include capecitabine, gemcitabine 1, clofara i e 
2 and cytarabine (Ara-C) 3 (Figure 1). 
 
Figure 1. Gemcitabine 1, clofarabine 2 and Ara-C 3. Modifications compared to native D-ribo-




























i 1. Gemcitabine 1, clofarabine 2 and Ara-C 3. Modifications compared to native d-ribo-configured
purine or pyrimidine nucleosid s are shown in blue.
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Therapeutic intervention using nucleoside analogues is not without its problems and their use
is often limited by poor cellular uptake, low conversion to the active triphosphate metabolite, rapid
degradation or clearance and development of resistance profiles in certain cell types [5,6]. Consequently,
research continues to develop next generations of nucleoside analogues that overcome some of these
limitations and provide new therapeutic options.
This class of antimetabolite also possess a proud history, and current frontline treatment, as
antiviral [7–12] and, more recently, antibacterial agents [13]. Indeed, the development of nucleoside
analogues has a symbiotic relationship between compound class and final therapeutic treatment. For
example, gemcitabine 1 was developed as an antiviral, but was subsequently shown to be very toxic to
leukaemia cells.
In this review, we survey developments from 2010 onwards for the chemical synthesis and
evaluation of modified nucleoside analogues for anticancer research. Specifically, focusing on alterations
to the native furanose ring (Figure 2) and generally retaining native purine or pyrimidine nucleobases.
Comprehensive reviews concerning hetero-base modifications and general trends in nucleotide
synthesis have been covered elsewhere [14,15]. The review is divided into sections that systematically
consider: i) furanose 4′-oxygen atom replacements with N, S, Se and C ii) 2′-, 3′-, 4′- or 5′-position
furanose ring modifications and iii) new prodrug approaches to deliver nucleoside analogues.
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2. Furanose Oxygen Atom Replacements 
2.1. Azanucleosides 
Azanucleosides were originally defined as nucleoside analogues where the furanosyl oxygen is 
replaced by nitrogen, however this group of analogues has been extended to include nucleosides 
where the resultant pyrrolidine core has been replaced by other nitrogen containing rings, including 
heterocycles, heterotricycles and acyclic nitrogen-containing nucleosides [16,17]. This class of 
compound have proven successful in the treatment of cancer [18] and have also been established as 
having antiviral and antibacterial properties [19].  
2.1.1. Development of Forodesine 
Purine nucleoside phosphorylases (PNPs) are responsible for the phosphorolytic metabolism of 
purine nucleosides to ribose/deoxyribose phosphate and the corresponding nucleobase. Patients with 
abnormally low levels of PNP possess little T-cell immunity due to a severely reduced degradation 
of deoxyguanosine, which results in the accumulation of the corresponding triphosphate (dGTP). 
This then reduces the activity of ribonucleotide reductase and induces apoptosis. As such, human 
PNP inhibitors are potential treatments for T-cell lymphomas [17]. Immucillin H (forodesine) 4 
(Figure 3) is a highly potent PNP inhibitor (IC50 = 0.48–1.57 nM) which is effective against T-cell 
malignancies and was found to have excellent oral bioavailability in mice (63%) [20].  
Forodesine is a gradual onset drug which binds tightly to PNP with a high affinity (Ki = 0.023 
nM) [21]. Whilst clinical development of 4 was discontinued in the US and Europe, it was recently 
approved for use in the treatment of relapsed/refractory peripheral T-cell lymphoma (PCTL) in Japan 
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2. Furanose Oxygen Atom Replacements
2.1. Azanucleosides
Azanucleosides were originally defined as nucleoside analogues where the furanosyl oxygen is
replaced by nitrogen, however this group of analogues has been extended to include nucleosides where
the resultant pyrrolidine core has been replaced by other nitrogen containing rings, including heterocycles,
heterotricycles and acyclic nitrogen-containing nucleosides [16,17]. This class of compound have proven
successful in the treatment of cancer [18] and have also been established as having antiviral and antibacterial
properties [19].
Development of Forodesine
Purine nucleoside phosphorylases (PNPs) are responsible for the phosphorolytic metabolism of
purine nucleosides to ribose/deoxyribose phosphate and the corresponding nucleobase. Patients with
abnormally low levels of PNP possess little T-cell immunity due to a severely reduced degradation of
deoxyguanosine, which results in the accumulation of the corresponding triphosphate (dGTP). This
then reduces the activity of ribonucleotide reductase and induces apoptosis. As such, human PNP
inhibitors are potential treatments for T-cell lymphomas [17]. Immucillin H (forodesine) 4 (Figure 3) is
a highly potent PNP inhibitor (IC50 = 0.48–1.57 nM) which is effective against T-cell malignancies and
was found to have excellent oral bioavailability in mice (63%) [20].
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13 with formamidine acetate and acidic removal of the silicon, nitrogen and isopropylidene 
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Scheme 1. Reagents and conditions: (i) NCS, pentane; (ii) LiTMP, −78 °C, 36% over two steps; (iii) 
nBuLi, MeCN, THF, −78 °C then tetramethylpiperidine −78 °C, 100%; (iv) (Boc)2O, CH2Cl2; (v) 
tBuOCH(NMe2)2, DMF, 70 °C; (vi) THF, AcOH, H2O, 72% from 7; (vii) H2NCH2CO2Et.HCl, NaOAc, 
MeOH (viii) ClCO2Bn, DBU, CH2Cl2, reflux, 67% from 10; (ix) H2, Pd/C, EtOH; (x) H2NCH=NH.AcOH, 
EtOH, reflux, 91% from 12 and (xi) TFA, 81%. 
Forodesine was found to have low oral bioavailability (<11%) in primates, contrary to the case 
in mice (63% [20]) and was thus originally developed as an intravenous formulation [21]. In 2005, 






















































































Forodesine is a gradual onset drug which binds tightly to PNP with a high affinity (Ki = 0.023 nM) [21].
Whilst clinical development of 4 was discontinued in the US and Europe, it was recently approved for use
in the treatment of relapsed/refractory peripheral T-cell lymphoma (PCTL) in Japan (April 2017) [22].
Forodesine is a guanosine analogue and a transition state inhibitor of PNP with 100–1000-fold
higher potency than previously identified inhibitors [23]. Due to the combined substitution of the
furanosyl oxygen with nitrogen and the C-glycosidic bond, 4 is not incorporated into DNA, acting
only as a highly selective PNP inhibitor [22]. Also noteworthy is an adenosine mi etic of 4 which is
currently under development as a broad-spectrum antiviral [24].
In 2000, Tyler et al. described a linear synthesis of 4 in a satisfactory 39% yield over 10 steps
(Scheme 1) [25]. Starting from 5, synthesised in nine steps by known methods from d-gulonolactone [26],
the pyrrolidine was treated with N-chlorosuccinimide (NCS), obtaining the 1-chloro anomeric glycoside
which subsequently underwent elimination using lithium tetramethylpiperidine (LiTMP) to afford
imine 6. The nucleobase was next assembled via addition of lithiated acetonitrile to afford 7, followed by
protection of the furanosyl nitrogen giving 8 and treatment with Bredereck’s reagent to afford enamine
9. Acid-catalysed hydrolysis of 9 delivered enol 10 which was reacted ith ethyl glycinate to obtain
enamine 11. Treatment of 11 with excess benzyl chloroformate and 1,8-diazabicyclo[5.4.0]undec-7-ene
(DBU) revealed 12 and subsequent hydrogenolysis of the N-Cbz group provided pyrrole 13. Completion
of the carbocyclic nucleobase was achieved via treatment of 13 with formamidine acetate and acidic
removal of the silicon, nitrogen and isopropylidene protecting groups, to afford 4.
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. ents and conditions: (i) NCS, penta e; (ii) LiTMP, − 8 ◦C, 36% over two steps; (iii) nBuLi,
CN, THF, −78 ◦C then tetramethylpiperidine −78 ◦C, 0%; (iv) (Boc)2O, CH2Cl2; (v) tBuO (NMe2)2,
DMF, 70 ◦C; (vi) THF, AcOH, H2O, 72% from 7; (vii) H2NCH2CO2Et·HCl, NaOAc, Me H (viii) ClC 2Bn,
DBU, CH2Cl2, reflux, 67% from 10; (ix) H2, Pd/C, EtOH; (x) H2NCH=NH·AcOH, EtOH, reflux, 91% from
12 an (x ) TFA, 81%.
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Forodesine was found to have low oral bioavailability (<11%) in primates, contrary to the case
in mice (63% [20]) and was thus originally developed as an intravenous formulation [21]. In 2005,
Morris, Jr et al. synthesised BCX-3040, the 2′-deoxy analogue of 4, and comparatively evaluated its
oral pharmacokinetic and pharmacodynamic properties in an effort to maintain potency and deliver
oral bioavailability [27]. This was hypothesised from 2′-deoxyguanosine exhibiting tight binding to
PNP [28] and therefore a possible redundancy for the 2′-OH. Starting from vinyl bromide 14 (Scheme 2),
the 9-deazapurine underwent bromine-lithium exchange and addition to imine 6, obtaining nucleoside
15 in 85% yield. Subsequent removal of 5′-O-TBS and 2′,3′-O-isopropylidene groups gave 16, followed
by 3′,5′-OTIPDS protection to afford 17. The free 2′-hydroxyl group was then converted to thiocarbonate
18 and deoxygenated via treatment with 1,1′-azobis(cyclohexane-1-carbonitrile) in excellent yield
(91%) to give 19. Deprotection was completed in two steps, first cleaving the CH2OCH2Ph (BOM)
group, followed by acidic hydrolysis and hydrochloride salt formation to obtain BCX-3040 in 83%
yield (from 19).
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BCX-3040, indicating a reduced bioavailability for BCX-3040. Furthermore, following IV 
administration of 5 mg/kg of BCX-3040, the plasma concentration of BCX-3040 dropped rapidly to 
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3040, it was concluded to be a poorer PNP inhibitor candidate in comparison to 4. 
2.2. Thionucleosides 
4′-Thiofuranoses are of known importance in biological systems, for example as chemical 
biology or biomedical tools [29], and possess chemotherapeutic activity [30,31]. Furthermore, the 
thioaminal moiety within 4′-thiofuranosyl nucleosides has been proven to be resistant to metabolic 
hydrolysis in comparison to native 4′-oxa analogues [32]. In the early 1990s, Secrist, Montgomery and 
co-workers stimulated interest in this class of molecule with their synthesis and biological evaluation 
Sche e 2. eagents and conditions: (i) 6, nBuLi, anisole, ether, −70 ◦ ; (ii) (Boc)2 , 2 l , 85 over
t o steps; (iii) 1M HCl, MeOH, 30 ◦C, 96%; (iv) 1,3-Dichloro-1,1-3,3-tetraisopropyldisiloxane, pyridine,
81%; (v) O-Phenyl chlorothionoformate, MeCN, 90%; (vi) 1,1′-Azobis(cyclohexane-1-carbonitrile),
toluene reflux, 91%; (vii) Pd(OH)2, H2, EtOH, conc. N 4OH, 90% and (viii) conc. HCl, MeOH,
reflux, 83%.
In vitro biological evaluation of BCX-3040 confirmed it to be a potent PNP inhibitor, with near
identical IC50 values to 4 (BCX-3040 IC50 = 3.1 ± 0.50 nM and 4 IC50 = 1.2 ± 0.21 nM). Administration
of 5.0 mg of 4 had a 12.6-fold greater 2′-deoxyguanosine response than administration of 10.0 mg of
BCX-3040, indicating a reduced bioavailability for BCX-3040. Furthermore, following IV administration
of 5 mg/kg of BCX-3040, the plasma concentration of BCX-3040 dropped rapidly to 3.0 ± 0.31 µg/mL.
Overall, due to the observed rapid clearance and reduced bioavailability of BCX-3040, it was concluded
to be a poorer PNP inhibitor candidate in comparison to 4.
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2.2. Thionucleosides
4′-Thiofuranoses are of known importance in biological systems, for example as chemical
biology or biomedical tools [29], and possess chemotherapeutic activity [30,31]. Furthermore, the
thioaminal moiety within 4′-thiofuranosyl nucleosides has been proven to be resistant to metabolic
hydrolysis in comparison to native 4′-oxa analogues [32]. In the early 1990s, Secrist, Montgomery and
co-workers stimulated interest in this class of molecule with their synthesis and biological evaluation
of 2′-deoxy-4′-thiopyrimidine nucleosides [30]. Since then, there has been a resurgence of interest in
the synthesis and evaluation of these compounds as potential antiviral and chemotherapeutic agents.
2.2.1. 2′-Modfied Thionucleosides
Yoshimura et al. reported the synthesis and biological evaluation of 4′-thia-1-(2-deoxy-2-C-methylene-
β-d-erythro-pentofuranosyl)cytosine (4′-thio-DMDC) 28β and 2′-deoxy-2′-fluoro-arabino-4′-thiacytidine
33β as potential antitumour agents [33–35]. Their synthesis of 28 started from 1,2,5,6-diisopropylidene-
d-glucose 20 and a series of protecting group manipulations delivered 3-O-benzyl d-xylose methyl
glycoside 21 (Scheme 3). Mesylation of the 2- and 5-hydroxyl groups enabled reaction with sodium
sulfide to afford 2,5-bicyclic intermediate 22 as a mixture of anomers. Following conversion of 22 to
4-thioarabinofuranose 23, the 2-position hydroxyl group was oxidised and the ketone homologated
using a Wittig reagent to install the 2-methylene component, with this material then oxidised to
sulfoxide 24.
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e ; (i ) a , e , 84 fr 20; ( ) 5 l/ e , 91 ; ( i) s l, ri i e; ( ii) a S,
F, -ano er 78 fro 21, -ano er 73 fro 21; (viii) 4 l, F; (ix) a , e , 90
fro 2; (x) TB PS l, i idazole, F, 87 ; (xi) c2 , S ; (xii) Ph P Br, a , t-a yl alcohol,
T F; (xiii) BCl3, C Cl , −78 ◦C then e , pyridine, 92 ; (xiv) -CPB , C 2Cl2, −78 ◦C, 74 fro
23; (xv) 25, T S Tf, ClC 2C Cl, 0 ◦C, 29 ; (xvi) TB F, T F and (xvii) aqueous 3, e then
PLC separation.
The cytidine nucleobase was installed using a Pummerer-type thioglycosylation, via sulphenium
ion 26, which afforded 27 as a mixture of anomers. These were fully deprotected to afford 28α and 28β
and the desired 28β isolated using HPLC separation.
Additionally, 2′-deoxy-2′-fluoro-arabino-4′-thiacytidine 33 was prepared from intermediate 23
(Scheme 4). Stereospecific DAST fluorination of 23 proceeded through epi-sulphonium intermediate
29 which delivered the 2-deoxy-2-fluoroarabino intermediate 30 in 68% yield. m-CPBA oxidation to the
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sulfoxide 31 and subsequent Pummerer rearrangement formed anomeric acetate 32 in 77% yield from
30. Finally, thioglycosylation was successfully employed to access the corresponding 4′-thionucleoside
mixture 33 (54% yield). Comparatively, the group found that using 32 as a donor and employing
silyl-Hilbert-Johnson glycosylation conditions yielded 33α/β in higher yield (93%), but still as a mixture
of anomers (2.9:1 α/β).Molecules 2020, 5, x 6 of 24 
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Finally, the group synthesised 2′-deoxy-2′-difluoro-1′(4′-thia-d-ribofuranose)cytosine 37, a
thionucleoside analogue of the potent chemotherapeutic agent gemcitabine 1 (Scheme 5). Intermediate
23 was again utilised and oxidised using Albright-Goldman conditions to obtain ketone 34 which was
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removed to afford 37α/β (α/β = 2.4/1) in a moderate yield of 51% from 36.
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The antineoplastic activities of 28, 33 and 37 were evaluated and compared to arabinocytidine 3
(Ara-C) and 1-(2-deoxy-2-C-methylene-β-d-erythro-pentofuranosyl)cytosine (DMDC) (Table 1). As
expected, all the α-anomer forms were found to be inactive against T-cell leukemia CCRF-HSB-2 cells.
However, the β-anomers showed considerable cytotoxic activity against the same cell line. Notably,
28β and 33β were highly potent against both T-cell leukemia CCRF-HSB-2 cells and human solid
tumour KB cells, with IC50 values of 0.01 µg/mL (CCRF-HSB-2) and 0.05 µg/mL (CCRF-HSB-2) for
28β and 33β, respectively. Indeed, the activity of 28β was significantly higher than that of its native
counterpart, DMDC, against both cell lines, with an IC50 value 2.4 times lower in CCRF-HSB-2 cells and
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3.7 times lower in KB cells. Interestingly, 4′-thiogemcitabine analogue 37β had poorer antineoplastic
activity compared to 1, which the authors suggest may be due to a reduction in the phosphorylation
efficacy of 37β by deoxycytidine kinase, a key enzyme which converts 2′-deoxycytidine analogues to
their corresponding monophosphates.
Table 1. Antineoplastic activities of 2′-modified-4′-thionucleosides.
Antineoplastic Activities IC50 (µg/mL)
Compound (Anomer) 2′-Substituent CCRF-HSB-2 a KB Cells b
28α =CH2 >10 ND c
28β =CH2 0.01 0.12
33α F (arabino) >10 ND
33β F (arabino) 0.05 0.02
37α F2 >10 ND
37β F2 1.5 17
Ara-C 3 0.05 0.26
DMDC 0.02 0.44
a MTT assay [36]; b dye uptake method [36]; c not determined.
2.2.2. 4′-Modfied-2′-deoxythionucleosides
Following earlier work by Parker and colleagues, who identified 4′-thia-2′-deoxycytidine (T-dCyd)
as being able to inhibit tumour growth [37], Haraguchi and colleagues reported the synthesis and
evaluation of a small library of 4′-position modified 4′-thia-2′-deoxycytidine nucleosides 38–41 for
their antineoplastic and antiviral activity (Figure 4) [38].
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38: R = N3 
39: R = CH2F
40: R = C≡C
41: R = C≡N
i . t t f ′- - ′-t i ti i l i .
Towards analogue 38 the group started from thioglycal 42 (Scheme 6), obtained using established
procedures from 2-deoxy-d-ribose in 12 steps [39]. This material was transformed into a glycosyl donor
through treatment with N-iodosuccinamide (NIS) and pivalic acid, giving one diastereoisomer of
2-iodo derivative 43. Silylated uracil was then glycosylated with 43 using Vorbrüggen-type conditions
to give β-4′-thiouridine 44 which was 2′-deoxygneated via a Bu3SnH mediated radical reduction
to give 45. Subsequent TIPDS deprotection, followed by C3′ and C5′-O-acetylation delivered 46 to
enable a four-step procedure to deliver 4′,5′-unsaturated-4′-thiouridine derivative 47. Exo-thioglycal
47 was next converted to silyl-protected 4′-thionucleoside 48, which when treated with Pb(OBz)4
yielded dibenzoate 49. SN2 inversion back to the native 4′-d-ribo configuration and 4′-azide installation
was achieved by reaction with MeSiN3 in the presence of SnCl4 and afforded the desired 4′-α-azido
derivative 50 as the major product. Finally, the nucleoside was converted to the cytidine form via
intermediate 51 to give 38 in 7% yield over 18 steps.
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. t conditions: (i) NIS, pivalic acid, MeCN/CH2Cl2, 93%; (ii) Uracil, N,O-bis
(trimethylsilyl)acetamide (BSA), TMSOTf, MeCN/ H2 l2, 87%; (iii) Bu3SnH, Et3B, toluene, O2, −60 ◦C,
98%; (iv) TBAF, c2O, THF, 100%; (v) NH3/MeOH; (vi) I2, PPh3, pyridine, dioxane; (vii) Ac2O, DMAP,
IPEA, CH2Cl2; (viii) BDN, MeCN, 65% over four steps; (ix) NH3/MeOH; (x) TBDMSCl, imidazole, DMF,
61% over two steps; (xi) Pb(OBz)4, toluene, 63%; (xii) TMSN3, SnCl4, CH2Cl2, 61%; (xiii) NaOMe, MeOH;
(xiv) Ac2 , DMAP, DIPEA, MeCN, 83% over two steps; (xv) TPSCl, K2O4, MeCN, 60 ◦C; (xvi) NH4OH,
THF; (xvii) TBAF, Ac2O, T F and (xviii) NaOMe, MeOH, 66% over four steps.
In order to access 2′-deoxy-4′-C-fluoromethyl-4′-thiacytidine 39, alcohol 53 was prepared from
known aldehyde 52 [40,41]. Treatment of 53 with DAST successfully installed the key 4-α-fluoromethyl
group which was then elaborated to 39 (Scheme 7). 4-α-alkynyl and nitrile analogues 40 and 41
were synthesised from aldehyde 54 using a late-stage insertion of the key functional group at the
4′-position in the presence of the nucleobase. Of the four 2′-deoxy-4′-modified thionucleosides 38-41,
two analogues, 38 and 39, showed moderate cytotoxicity against human B-cell leukaemia (CCRF-SB;
IC50 = 7.14 µM and 3.19 µM for 38 and 39 respectively) and human T-cell leukaemia cell lines (Molt-4;
IC50 = 2.72 µM and 2.24 µM for 38 and 39 respectively).
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c e e 7. ey inter e iates to access 2′- eoxy-4′-thiocyti ine nucleosi es 39–41.
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2.3. Selenonucleosides
A first synthesis of pyrimidine 4′-selenonucleosides was reported by Jeong and colleagues in 2008
(Scheme 8), [42] starting from lyxose derivative 55, synthesised from d-gulonic-γ-lactone in four steps
using established procedures [43].
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presence of NaBH4. Oxidation of 59 to a diastereomeric selenoxide mixture 60 then enabled either a 
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65: R1 = F; R2 = NH2
66: R1 = OH; R2 = NH2
67: R1 = F; R2 = OH
68: R1 = OH; R2 = OH
. Reagents and conditions: (i) TBDPSCl, Et3N, DMAP, CH2Cl2, 92%; (ii) NaBH4, MeOH,
98%; (iii) MsCl, Et3N, DMAP, CH2Cl2, 97%; (iv) Se, NaBH4, EtOH, THF, 60 ◦C, 96%; (v) m-CPBA,
CH2 l2, −78 ◦C, 85%; (vi) Uracil, Et3N, TMSOTf, toluene, CH2Cl2, 53%; (vii) 50% aq. TFA, 81%; (viii)
N3-benzoylcytosine, Et3N, TMSOTf, toluene, CH2Cl2, 35%; (ix) 50% Aq. TFA and (x) 3, eO , 82
over t o steps.
Selective protection of the primary alcohol in 55 was achieved by reaction with TBDPSCl, giving
hemiacetal 56 which was reduced with NaBH4, furnishing diol 57. Following double mesylation of 57
to give 58, cyclisation to give 4-selenosugar 59 was achieved by treatment with selenium in the presence
of NaBH4. Oxidation of 59 to a diastereomeric selenoxide mixture 60 then enabled either a uracil or
cytosine nucleobase to be installed via a Pummerer-type glycosylation, furnishing the β-anomers 61 or
63. 4′-selenouridine 62 was obtained after global deprotection of 61 with 50% aqueous TFA in an overall
yield of 12% over 11 steps. 4′-selenocytidine 64 was similarly obtained in an overall yield of 9% over
11 steps. The crystal structure of 62 revealed the non-native ring adopted an unusual C2′-endo/C3′-exo
twist (Southern confirmation), contrary to uridine, which shows a C2′-exo/C3′-endo twist (Northern
conformation). This difference was explained by the introduction of the bulky selenium, whereby
stereoelectronic effects observed in 4′-oxanucleosides are outweighed by the size of the heteroatom.
2′-Substituted-4′-selenoribofuranosyl Pyrimidines
Building on their work in this area, Jeong and co-workers reported the synthesis and biological
evaluation of a small library of 2′-substituted 4′-selenoarabinofuranosyl pyrimidine analogues 65–68
(Figure 5) [44,45].
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65: R1 = F; R2 = NH2
66: R1 = OH; R2 = NH2
7    O
8 O
i r . tr t r f ′- tit t ′- l r i f r l ri i i l .
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A 2′-fluoroarabino analogue was obtained via a 2′-position DAST fluorination of intermediate 69,
synthesised from 4′-selenouridine 61 using a four-step process [44]. At first attempt, DAST fluorination
of 69 led to the formation of the desired 2′-fluoro product 70 as the minor product in 23% yield,
along with a major product, 2,2′-O-anhydro nucleoside 71, in 60% yield (Scheme 9). This ratio was
subsequently improved by instead fluorinating an N3-benzoyl derivative 72, giving 73 in 45% yield,
now as the major product, and 71 in reduced 30% yield.
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. Reagents and conditions: (i) DAST, CH2Cl2, −78 ◦C, 23%; (ii) TESCl, DMAP, H2Cl2;
(iii) BzCl, pyridine, DIPEA, 70 ◦C; (iv) TBAF, THF, 0 ◦C, 81% ove thre steps and (v) DAST, CH2Cl2,
−78 ◦C, 45%.
Following global deprotection and uracil to cytosine conversion, four nucleoside analogues 65–68
were evaluated against several human cancer cell lines (HCT116, A549, SU638, T47D, PC-3 and K562)
and compared to the established anticancer nucleosides 1 and 3 (Table 2). From this study, it was
found that 2′-fluoro-4′-selenoarabinocytidine 65 was the most potent analogue, showing even greater
potency than 3, in the majority of cell lines tested.
Table 2. Anticancer activity of 2′-modified 4′-selenoarabino nucleosides 65–69 compared to 1 and 3
across several human cancer cell lines.
IC50 (µM)
Compound HCT116 a A549 b SNU638 c T4 d PC-3 e K562 f
65 1.1 0.47 0.14 0.79 0.58 0.63
66 7.13 8.83 4.72 ND ND 86.6
67 >100 >100 >100 >100 >100 >100
68 >100 >100 >100 >100 >100 >100
3 5.30 1.90 0.15 2.70 55.9 0.05
1 0.01 0.09 ND ND 0.04 ND
Human cancer cell tiss e a ; b ; c ach; d reast; e prostate; f myelogenous leukemia.
The group have also reported further 2′-substituted-4′-selenoribofuranosides [46], synthesising a
series of pyrimidine 2′-substituted analogues and utilising a 2,2′-O-anhydro intermediate to enable
regioselective nucleophilic ring opening to the desired ribo-configured products (Figure 6). Only a
2′-fluoro riboselenocytosine derivative showed significant activity (uracil, thymine and 5-halo uracil
derivatives showed no activity up to 100 µM), but this was less potent than the arabino-configured
analogue previously described [45].
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Figure 6. 2′-Substituted-4′selenoribofuranosyl nucleosides reported by Jeong.
2.4. Carbocyclic Nucleosides
In carbocyclic nucleosides the furanosyl oxygen is replaced by CH2, forming a cyclopentane ring.
The lack of a hemiaminal linkage between the nucleobase and the sugar leads to an increased chemical
stability. Furthermore, due to the lack of a glycosidic bond, these nucleosides show an enhanced
resistance towards phosphorylases [47]. Although considered a second generation of nucleoside
analogues, there are two naturally occurring carbocyclic nucleosides, aristeromycin 74 and neplanocin
A 75 (Figure 7), both of which exhibit substantial biological activity as antitumor agents [47].
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2.4.1. Fluorinated Derivatives of Neplan cin A
In 1988, Driscoll et al. reported that a cytosine analogue (CPE-C) of 75 showed substantial
antitumour and antiviral activity [48]. On the basis of these findings, and the continuing clinical success
of fluorine containing nucleoside chemotherapeutics [49,50], Jeong et al. subsequently reported the
synthesis and biological evaluation of a small library of fluorocyclcopentenyl pyrimidine nucleosides
76–79 (Figure 8) [51].
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i r . tr ct r s f fl r c cl t l cl si l s .
Fluorocyclopentenyl cytosin 76 was synthesised from cyclope tenone 80 (Scheme 10), which
was obtained from d-ribose in nine steps using established procedures [52,53]. Iodination of 80 was
accomplished by treatment with I2 and pyridine in THF, to give 81. Stereo- and regioselective reduction
of 76 was achieved using Luche conditions to give 82, followed by TBDPS protection of the resulting
alcohol to deliver 83. Following lithium-halogen exchange of 83 using n-BuLi, electrophilic fluorination
was achieved by treatment with N-fluorobenzenesulfonimide (NFSI). Anomeric desilylation with
TBAF then gave 84 to which a uracil nucleobase was installed via condensation with N3-benzoyluracil
under Mitsunobu conditions. Finally, global deprotection was achieved by sequential treatment with
methanolic ammonia and BBr3, providing uracil derivate 85 which was converted to 76 via a standard
four-step process.
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Of the four nucleoside analogues evaluated (Figure 8), derivative 76 showed significant potency
against several human cancer cell lines (Table 3) [51,54,55]. Furthermore, Jeong reported that 76 also
showed significant antitumour activity in a nude mouse xenograft model implanted with A549 human
lung cancer cells, wherein after 38 days the inhibition of tumour growth was 32% and 58% at 3 and
10 mg/kg doses, respectively [54].
Table 3. Anticancer activity of 76 in human cancer cell lines.
Cancer Cell Line
HTC-116 a MDA-MB-231 b PANC-1 c MCF-7 d A549 e MKN45 f U251 g
IC50
(µM) 0.39 0.18 0.62 0.34 0.34 0.50 0.83
Human cancer cell tissue type a colon; b breast; c pancreatic; d hormone-dependent breast; e lung; f stomach; g brain.
Carbocyclic nucleoside 76 has now been evaluated in more than 100 different cell lines, as well as
several xenograft models, showing high potencies against numerous types of cancer, including
gemcitabine resistant cell lines [56,57]. Pharmacokinetics and oral bioavailability for 76 were
investigated in phase 0 clinical trials, wherein a small cohort of patients were administered a single oral
dose (50 mg or 100 mg) of 76, or a single intravenous dose (20 mg, Table 4) [58]. This study found that
the absolute bioavailability for 76 was 56% and 33% for 50 and 100 mg doses, respectively, suggesting
it not to be dose-proportional. However, t1/2 was found to be 14 h and 21 h for 50 and 100 mg doses,
respectively. This may suggest that 76 does exhibit some dose proportionality in some parameters, but
not in others and it was noted that this result may be due to the small patient sample size. Analogue
76 is currently in phase II clinical trials for metastatic pancreatic cancer and advanced bladder cancer.
Table 4. Pharmacokinetic data for 76 from phase 0 clinical studies.
Dose (mg) Tmax (h) Cmax (ng/mL) t1/2 (h) Oral Bioavailability (%)
20 * 0.3 1144 - -
50 2.2 303 14 56
100 2.5 311 21 33
* Intravenous.
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2.4.2. Norbornane-Derived (C2′,C4′-bridged) Carbocyclic Nucleosides
Nencka and colleagues reported the synthesis of norborane, C2′,C4′-bridged carbocyclic
nucleosides [59], with a hypothesis of locking the nucleoside analogue in the 2′-exo or North
conformation which has garnered attention in the field of carbocyclic antiviral nucleoside analogue
development [60]. To access these compounds their synthesis started from known hydroxy ester 86
which was stereochemically inverted at the C1 position via an oxidation-reduction sequence to deliver
87 (Scheme 11). This enabled the desired stereochemistry to be attained at C1 when subsequently
inserting an azide by nucleophilic displacement of a mesylate to afford 88 which was reduced to
give 89. With scaffold 89 in hand, the group then elaborated the amine at C1 to several purine and
pyrimidine nucleobase forms (including C6 purine analogues) and evaluated their cytotoxic potential.
From this series, derivatives 90 and 91 showed IC50 activities below 100 µm in human T-lymphocyte
(CEM) cells (IC50 = 88 µM for 90 and IC50 = 78 µM for 91), but no significant activity was observed in
murine leukemia (L1210) or HeLa cell lines.
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in vitro at a single high dose (10−5 M) in the full NCI 58 human tumor cell screen panel. 
Phenethylamine derivative 95 exhibited growth inhibition of 74% on SK-MEL-5 melanoma and UO-
31 renal cancer cell lines, but was not deemed sufficiently cytotoxic for studies to proceed further. 
The group followed up this report with further synthesis of 6-position carbocyclic analogues [62], 
derived from 94, noting that a 6-(4-methoxy-phenethyl)amino group was active, but again the 
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2.4.3. C3’,C5’-Bridged Carbocyclic L-Nucleosides
Tănase and colleagues reported the synthesis of an alternative carbocyclic system based on a
similar bicyclo[2.2.1]heptane fragment, accessing a small series of 3’-5’-linked L-nucleoside analogues
containing C6-amino modifications (Scheme 12) [61]. Their synthesis started from known alcohol 92
and proceeded through azide incorporation (to give 93) and reduction steps in good yields to deliver
amine 94. The 6-chloropurine ring was then introduced using standard methods and elaborated
at C6 with a series of amines via nucleophilic aromatic substitution. This small library was then
screened in vitro at a single high dose (10−5 M) in the full NCI 58 human tumor cell screen panel.
Phenethylamine derivative 95 exhibited growth inhibition of 74% on SK-MEL-5 melanoma and UO-31
renal cancer cell lines, but was not deemed sufficiently cytotoxic for studies to proceed further. The
group followed up this report with further synthesis of 6-position carbocyclic analogues [62], derived
from 94, noting that a 6-(4-methoxy-phenethyl)amino group was active, but again the analogue was
not progressed further.
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Scheme 13. Reagents and conditions: (i) TIPSCl, imidazole, DMF, 92%; (ii) NFSI, LiHMDS, THF, −78 
°C, 72%; (iii) DIBAL-H, toluene, −78 °C, 91%; (iv) MsCl, Et3N, CH2Cl2, quant.; (v) 2,6-dichloropurine, 
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3.2. 2’-O,4-C’-Bridged Nucleosides 
In 2011, Nicolaou and colleagues reported the synthesis and evaluation of a small library of 2’,4’- 
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3. 2′-, 3’- and 5’-Furanose Ring Modifications
3.1. 2′-Furanose Modifications
Clofarabine 2 (Figure 1) is a purine nucleoside analogue which, in its corresponding 5’-O-
triphosphate form, inhibits both ribonucleotide reductase and DNA polymerases and prevents effective
DNA synthesis. Ultimately, this leads to cell apoptosis, particularly in rapidly proliferating and
dormant cancer cells. The nucleoside analogue exhibits excellent cytotoxic activity in vitro, with an
IC50 range of 0.028–0.29 µM across a variety of solid tumour and leukaemia cell lines [63], alongside
substantial tissue distribution and a half-life of at least 24 h for the active triphosphate metabolite [64].
The use of 2 for treatment of paediatric patients with relapsed or refractory acute lymphoblastic
leukaemia was approved by the food and drug administration (FDA) in 2004, the first nucleoside
analogue of its kind to be approved in over a decade [65].
In 2010, Sauve and colleagues reported an improved, stereoselective synthesis of 2 [66], in an
overall yield of 38% (Scheme 13). This compared favourably to a prior report by ILEX Products Inc.,
which detailed an overall yield of 14% in six steps, starting from a fully protected ribose derivative.
Sauve’s work began from commercially available lactone 96 with 3,5-O protection using TIPS affording
97, which was then diastereoselectively fluorinated at the 2-position, obtaining the arabino-configured
98 exclusively in 72% yield. Conversion to the anomeric chloride (via hemi-acetal 99) delivered 100
which was condensed with 2,6-dichloropurine to afforded 101 in 66% yield over two steps and a
β/α ratio of 3.5:1. Access to 2 was gained following diastereomeric separation of 101, 4-position
ammonolysis and deprotection.
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3.2. 2′-O,4-C’-Bridged Nucleosides
In 2011, Nicolaou and colleagues reported the synthesis and evaluation of a small library of 2′,4′-
and 3’,4′-bridged nucleoside analogues, presenting conformationally restrained 3’-endo (North) and
2′-endo (South) systems [67]. These compounds were evaluated for their antiviral, antitumour and
antibacterial properties, with 2′,4′-bridged purines 105 and 106 showing µM inhibitory activity against
CEM (IC50 = 0.36 µM for 105 and 7.6 µM for 106) and Raji (IC50 = 0.25 µM for 105 and 5.8 µM for 106)
cancer cell lines.
The synthesis of 105 and 106 derived from a common 4-disubstituted acetate 102, available using
established chemistry from diacetone-d-glucose (Scheme 14) [68,69]. The group used Vorbrüggen
glycosylation of either 2,6-diaminopurine or 2,6-dicholoro-9H-purine to afford 103 or 104 respectively,
with the substitution proceeding in good yields (100% for 103 and 64% for 104), but noting a requirement
to control the amount of N,O-bis(trimethylsilyl)acetamide (BSA) used to silylate the purine to 2.5
equivalents. 2′,4′-bridged compound 105 was constructed via base mediated cyclisation between C2′
and C4′, followed by per-benzoylation of purine nitrogen and silicon protecting group removal.
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To access allyl substituted 2′,4′-system, Stille couplings were completed at positions 2 and 6 of
the purine, followed by a similar base-mediated C2′ deacetylation and intramolecular cyclisation
to afford, after C5’-protecting group removal, 106. Isomerisation of the allyl group at C6 of the
purine ring was observed during the palladium and base-mediated cyclisation steps. The antitumour
activities of 105 and 106 were considerably lower than for the known anticancer nucleoside cladribine
(CEM IC50 = 0.5 nM and Raji IC50 = 9.0 nM), as was the activity (IC50 >10 µM) of the 2′4′-bridged
analogue of cladribine, suggesting that the inclusion of this conformational restraint or the addition of
an extra CH2O unit was enough to remove antitumour properties.
3.3. 3’-Modified Nucleosides
Cheng and co-workers reported an asymmetric synthesis of 2′,3’-dideoxy-3’-boronic acid
pyrimidine nucleosides [70]. The group used two highly diastereoselective reactions of chiral
boronic esters with (dihalomethyl)lithium reagents to install the ultimate stereochemistry required
at C3’ and C4′ (Scheme 15). Starting from (S,S)-1,2-dicyclohexyl-1,2-ethanediol (DICHED) derived
boronate ester 107, homologation was completed with (dichloromethyl)lithium to afford 108, the
newly formed stereochemistry of which was inverted to give boronate ester 109. The chiral auxiliary
component was next switched from DICHED to a pinanediol (derived from (+)-pinene), delivering 110.
A second diastereoselective homologation was completed with (dibromomethyl)lithium, affording
bromo boronic ester 111. Nucleophilic displacement and inversion of this bromide with allylmagnesium
bromide followed by oxidative cleavage of the alkene afforded aldehyde 112. Hydrogenolysis of
the C4-O-Bn group in 112, concomitant cyclisation and anomeric acetylation delivered the final
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2-deoxy-ribo configured scaffold 113. This was divergently converted to a series of pyrimidine
containing nucleoside analogues containing a unique C3’-boronic acid. Unfortunately, biological
evaluation of these compounds demonstrated no significant cytotoxicity towards the HepG2 cell line
and all derivatives were observed to undergo gradual hydrolytic cleavage under biological conditions.
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Scheme 15. Reagents and conditions: (i) LiCHCl2, THF then ZnCl2; (ii) PhCH2ONa, 97%;
(iii) Pinanediol, Et2O, H2O, 96%; (iv) CH2Br2, LDA, THF then ZnCl2, 83%; (v) CH2CHCH2MgBr, 86%;
(vi) NaIO4/K2OsO4, 2,6-lutidine, dioxane/H2O, 63%; (vii) H2 Pd/C, EtOAc, 81% and (viii) Ac2O,DMAP,
CH2Cl2, 98%. Cy = cyclohexyl, T = thymine, 5F-U = 5-fluorouracil, C = cytosine, 5I-U = 5-iodouracil.
More recently, Borbas and colleagues reported a small library of 3’-deoxy-3’-thio substituted
xylofuranosyl pyrimidines [71]. Utilising a photoinduced thiol-ene reaction the workers were able to
effect addition of several different thiols to an appropriately protected 3’-exomethylene ribopyrimidine
system. This afforded d-xylo configured products in high diastereomeric excess which were shown to
have cytostatic activity in the low micromolar range.
3.4. C5′-N-Cyclopropylcarboxamido-C6-amino-C2-alkynylated Analogues
In 2017, Mohan et al. synthesised and evaluated a series of C5′-N-cyclopropylcarboxamido-
C6-amino-C2-alkynylated purine nucleoside analogues (Scheme 16) [72]. Starting from guanosine,
the group accessed C2-aryl iodide derivative 114 which was oxidised at C5’ using KMnO4, followed
by amide coupling to install the C5′-N-cyclopropylcarboxamido group. Following 2′,3’-O-acetonide
removal, the C2-iodide underwent a series of divergent Sonogoshira couplings to deliver a library of
seven purine analogues. From this library, compounds 115 and 116 showed in vitro cytotoxic effects
comparable to doxorubicin against human breast (MDA-MB-2312) and human colon (Caco2) cell lines.
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3.5. 5′-β-Hydroxyphosphonate Analogues
In 2014, Peyrottes and co-workers reported their synthesis of a series of β-hydroxyphosphonate
nucleosides, targeting 2′ and 3’ hydroxyl group stereochemistry changes and the introduction of
5-position substituents to the nucleobase (Figure 9) [73]. This report built upon the group’s earlier
work developing this class of compound as 5’-nucleotidase inhibitors (specifically the cytosolic cN-II
5’-nucleotidase II) [74]. These enzymes catabolise nucleoside 5’-monophosphates and their expression
level is of crucial interest for patients undergoing nucleoside analogue chemotherapy, with a higher
expression level often associated with a worsened clinical outcome [75].
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Tucker and colleagues recently described their synthesis of ferronucleosides, an important new 
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HeLa and CEM), both 118 and 119 had activities in the low µM range, with 118 and 119 20 to 50-fold 
more active than 5F-U in CEM cell cultures (0.9 µM for 118, 0.35 µM for 119 versus 18 µM for 5F-U). 
The compounds also performed promisingly in cell growth inhibition (oesophageal cancer cell line) 
and cellular viability (MTT assay) studies, with the data indicating that both functional groups 
appended to the ferrocene component were required for optimum cytostatic activity.  
Figure 9. 5’-β-Hydroxyphosphonate analogues developed by Peyrottes and active compound 117 from
this series, Y = NH2 or OH.
The group completed the synthesis of a library of 32 β-hydroxyphosphonate analogues which
included d-allo, d-altro, d-manno and d-gluco configurations of the furanose 2′- and 3’-positions along
with C2′-C3’ ring opened derivatives. They also installed alkynyl, aryl or ethenylaryl groups at C5 of the
cytidine or uridine nucleobase using transition-metal cross-couplings of the corresponding C5-iodide.
Biological activity data was obtained using recombinant, purified cN-II with inosine monophosphate
as substrate. From the resultant SAR study, cytosine-based analogues were generally more active than
their uracil counterparts, but the configurational isomers at C2′ or C3’ were generally less active than
the parent compounds (allofuranose). Modification of the nucleobase was generally well tolerated
with an observed Ki value of 1.14 mM for phenylethenyl substituted derivative 117 (Figure 9), noting
that high substrate concentrations (in the mM range) are required for activity with cN-II.
3.6. Ferronucleosides
Tucker and colleagues recently described their synthesis of ferronucleosides, an important new
development in the field of medicinal bioorganometallic chemistry [76]. Here the furanose ring was
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exchanged for the five-membered cyclopentadienyl ring of a ferrocene unit, but retained the nucleobase
and hydroxymethyl group as key components appended in a 2,3 relationship to the ferrocene core
(compounds 118 and 119, Figure 10). Using thymine or adenine as the nucleobase, the compounds
were tested with a control series (where the hydroxymethyl or base component were absent) for their
cytostatic activity and compared to established chemotherapeutic agents 5-fluorouracil (5F-U) and
cisplatin. In a proliferation activity assay on three tumour cell lines (L1210, HeLa and CEM), both
118 and 119 had activities in the low µM range, with 118 and 119 20 to 50-fold more active than 5F-U
in CEM cell cultures (0.9 µM for 118, 0.35 µM for 119 versus 18 µM for 5F-U). The compounds also
performed promisingly in cell growth inhibition (oesophageal cancer cell line) and cellular viability
(MTT assay) studies, with the data indicating that both functional groups appended to the ferrocene
component were required for optimum cytostatic activity.Molecules 2020, 25, x 18 of 24 
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4.2. Vitamin E Phosphate Prodrugs 
Nucleoside analogue therapy can suffer from inducive and constitutive resistance, which limits 
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displayed anticancer activity. As such, vitamin E phosphate nucleoside analogue prodrugs were 
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4. Nucleoside Analogue Prodrugs
4.1. Phosphorodiamidate Prodrugs
In 2018, Slusarczyk’s team reported the synthesis of phosphorodiamidates for a series of
established anticancer nucleoside analogues [77]. This was envisioned following the successful
ProTide technology developed by McGuigan [78], to deliver nucleoside monophosphate analogues
into cells and recent reports of phosphorothioamidate systems [79]. A lack of chirality at phosphorous
in a phosphorodiamidate was envisioned to confer advantages in not having to resolve diastereomeric
mixtures, often a requirement in earlier generations of ProTides, as SP and RP diastereoisomers exhibited
markedly different biological activities [80]. Accordingly, seven different anticancer nucleosides (1,
FUdR, 8-chloroadenosine, fludarabine, AraG, thioinosine and thioguanosine) were converted to their
phosphorodiamidate form using a one-pot, two-stage strategy (Scheme 17). First the 5’-OH was
converted to a phosphorodichloridate intermediate 120, followed by double phosphoramidation using
an appropriate amino acid ester salt. The panel of analogues were then evaluated in vitro against
a wide range of solid tumour and haematological cell lines with the potential for this approach
confirmed for FUdR and 8-chloroadenosine, where similar or improved inhibitory activities compared
to the parent nucleosides were observed. FUdR and its phosphorodiamidate prodrug showed activity
in the sub-micromolar range with IC50 values of 0.0046–0.073 µM for FUdR and 0.01–0.40 µM for
the FUdR phosphorodiamidates against the wild-type cell lines. Also of note was the inactivity
of arabino configured analogues, suggesting conversion to the monophosphate might be prevented
through their being poor substrates for phosphoramidase activity [81]. Enzymatic studies were
undertaken to investigate the bioactivation pathway of this class of nucleoside prodrug with a
carboxypeptidase Y assay and 31P-NMR confirming the hydrolysis of both esters followed by loss of
one phosphoramidate group.
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4.2. Vitamin E Phosphate Prodrugs
Nucleoside analogue therapy can suffer from inducive and constitutive resistance, which limits
the efficacy of the treatment. Isoforms of vitamin E, in particular δ-tocopherol and tocotrienols
have displayed anticancer activity. As such, vitamin E phosphate nucleoside analogue prodrugs
were envisaged to combat two mechanisms of resistance: i) downregulation of metabolic kinases
(deoxycytidine kinase, dCK, in the case of 1) and ii) nucleoside transport [82,83]. Accordingly, Daifuku
and co-workers synthesised and evaluated four isoforms of vitamin E conjugated to 1 (Figure 11,
compounds 121–124) [84].
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The in vitro GI50 of 1, vitamin E phosphate (VEP) isoforms and compounds 121–124 showed
these VEP-gemcitabine prodrugs to exhibit anticancer activity, consistent with their catabolism to
vitamin E and gemcitabine monophosphate. Conjugate 122 displayed the best activity with GI50 values
<5 µM in breast MDA (MB-231), non-small cell lung (NCI-H460) and colon (HCT-116) cell lines. The
authors suggested this was due to steric hindrance, from the methyl groups proximal to the vitamin
E-phosphate bond, reducing the rate of enzymatic cleavage to the monophosphate counterpart.
Prodrugs 122 and 123 were then evaluated in the presence of an inhibitor of nucleoside transport,
dipyridamole (DP, Table 5) with the data indicating that both were largely unaffected by the presence of
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DP in comparison to 1. This suggested that these prodrugs bypass nucleoside membrane transporters
and may thus be beneficial in the treatment of patients with gemcitabine resistant cells.








Compound DP (−) DP (20 µM) DP (−) DP (20 µM) DP (−) DP (20 µM)
1 3.08 56.8 0.02 0.82 0.03 2.39
122 30.3 27.8 7.16 16.0 5.55 12.6
123 17.2 23.3 2.14 1.47 3.07 6.74
In particular, as conjugate 123 displayed significant potency against the three DP(-) cell lines and
moderate potency against the DP-dosed cell lines (Table 5), it was selected to further compare activity
against 1 in in vitro wild-type leukemic CEM cells and CEM cells deficient in dCK. In dCK(−) cells 1 is
not phosphorylated, with GI50 values increasing from 0.002 µM in wild-type to 124.5 µM in dCK(−).
For 123 the GI50 increase was significantly lower than that of 1 (from 0.59 µM to 19.2 µM). Furthermore,
the half-life of 123 in mice was shown to be 4 h, a 13.9-fold increase to that of 1 (0.3 h [85]). Overall,
this study showed an interesting proof of concept for VEP-1 prodrugs against resistant cancer cell
lines. However, further optimisation will be required to obtain promising candidate compounds with
increased potencies.
5. Conclusions
Nucleoside analogues are an historically accomplished class of drugs with highly diversifiable
scaffolds and proven potential to treat a wide range of cancer cell types. Recent synthetic trends
have focused on furanose oxygen substitution with heteroatoms or carbon and fluorocyclopentenyl
cytosine is proving a promising new clinical candidate in this regard. Alongside this, examples
of templating such modifications onto established nucleoside analogue scaffolds, such as Ara-C
and forodesine, are emerging. As further pharmacokinetic and pharmacodynamic parameters are
evaluated for these architectures, their pharmaceutical utility will be established. Finally, the continued
advancement of prodrug strategies to deliver these compounds more effectively and provide options to
treat drug-resistant cancer cell types sets an exciting future for nucleoside analogue chemotherapeutics
and the underpinning requirement of chemical synthesis in realising this.
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